Abstracts tagged "classification criteria"

Abstract Number: 0183 • ACR Convergence 2024
Sensitivity of 2019 EULAR/ACR SLE Criteria and Initial Organ Manifestations for Black and Hispanic Children with Juvenile Systemic Lupus Erythematosus (jSLE) at a Large Tertiary Care Center
Michelle Butts¹, Emily Beil¹, Danielle Guffey², Andrea Ramirez¹, Cagri Yildirim-Toruner³, Erin Peckham-Gregory¹ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disorder with diverse features, posing classification challenges. In 2019, EULAR and ACR developed new classification criteria to…
Abstract Number: 0549 • ACR Convergence 2024
Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study
Nelly Ziade¹, Sherif Gamal², Maroun Aoun³, Ihsane Hmamouchi⁴, Clementina López Medina⁵, Maxime Dougados⁶ and Bassel Elzorkany⁷, and ASAS-PerSpA, ¹Saint-Joseph University, Beirut, Lebanon, ²Cairo University, Cairo, Egypt, ³Saint Joseph University, Beirut, Lebanon, ⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, ⁵Reina Sofia University Hospital, Cordoba, Spain, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Private (BZRC), Cairo, Egypt
Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…
Abstract Number: 0612 • ACR Convergence 2024
Performance of the Systemic Lupus Erythematosus Risk Probability Index (SLERPI): Results from the Egyptian College of Rheumatology (ECR) Study Cohort
Nevin Hammam¹, Ahmed Elsaman², Esam Abualfadl³, Soha Senara⁴, Nada M. Gamal⁵, Mona H. Abd Elsamea⁵, Abdelhfeez Moshrif⁶, Samar Tharwat⁷, Osman Hammam⁸ and Tamer A Gheita⁹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Boston, MA, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt; Qena/Luxor Hospitals, Qena, Egypt, Sohag, Egypt, ⁴Rheumatology Department, Faculty of Medicine, Fayoum University,, Fayoum, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, Assiut, Egypt, ⁶Al-azhar university, Assiut, Egypt, ⁷Rheumatology Unit, Internal Medicine, Mansoura University, Dakahlia, ⁸Department of Rheumatology and Rehabilitation, Faculty of Medicine, New Valley University, New Valley, Assiut, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a great heterogeneity and unpredictable flare. In managing patients with SLE, the diagnosis…
Abstract Number: 1901 • ACR Convergence 2023
Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Ørnbjerg¹, Brigitte Michelsen², Tore Kvien³, Daniela Di Giuseppe⁴, Johan Karlsson Wallman⁵, Jakub Zavada⁶, Sella Provan⁷, Ana Maria Rodrigues⁸, Maria Jose Santos⁹, Ziga Rotar¹⁰, Dan Nordstrom¹¹, Anna-Mari Hokkanen¹², Gary Macfarlane¹³, Gareth T. Jones¹³, Irene van der Horst-Bruinsma¹⁴, Pasoon Hellamand¹⁵, Mikkel Østergaard¹⁶ and Merete Hetland¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ³Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁷Diakonhjemmet Hospital, Oslo, Norway, ⁸Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ⁹Hospital Garcia de Orta, Almada, Lisboa, Portugal, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Helsinki University and Helsinki University Hospital, Helsinki, Finland, ¹³Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹⁴Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands, ¹⁵Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: When assessing disease activity in patients with axial spondyloarthritis (axSpA), the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over ASDAS…
Abstract Number: 1943 • ACR Convergence 2023
IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria
Pablo Martínez Calabuig¹, Jorge Juan Fragio¹, Roxana Gonzalez Mazarío², Amalia Rueda Cid³, Mireia Lucía Sanmartín Martínez¹, Laura Salvador Maicas¹, Laura Abenza Barberá¹, María Cristina Sabater Abad¹, Antonio Sierra Rivera¹, Inmaculada Castelló Miralles¹, Juan José Lerma Garrido¹, Clara Molina Almela³, Isabel Balaguer Trull¹ and Cristina Campos Fernández¹, ¹Hospital General Universitario Valencia, Valencia, Spain, ²Hospital de Sagunto, Valencia, Spain, ³Hospital General de Valencia, Valencia, Spain
Background/Purpose: IgG4 immunoglobulin-related disease (IgG4-RD) is a rare, systemic immune-mediated fibro-inflammatory process with an unclear etiology and pathophysiology with the capacity of affecting multiple organs.…
Abstract Number: 2264 • ACR Convergence 2023
Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes
Ivonne Lourdes Mamani Velarde¹, Iñigo Rúa-Figueroa², Sara García Pérez¹, Irene Altabás González³, CORAL Mourino Rodriguez⁴, Norman Jiménez⁵, JULIA MARTINEZ BARRIO⁶, Maria Galindo-Izquierdo⁷, Jaime Calvo- Alén⁸, Celia Eurasquin⁹, Belen Serrano Benavente¹⁰, Esther Uriarte Isacelaya¹¹, Eva Tomero Muriel¹², Mercedes Freire González¹³, Ricardo Blanco¹⁴, Eva Salgado-Pérez¹⁵, Paloma Vela¹⁶, Antonio Fernandez-Nebro¹⁷, Alejandro Olivé-Marqués¹⁸, Clara Sanguesa Gomez¹⁹, Javier Narvaez²⁰, Raúl Menor-Almagro²¹, Jose Rosas²², José Ángel Hernández Beriain²³, JAVIER MANERO²⁴, Elena Aurrecoechea Aguinaga²⁵, Oihane Ibarguengoitia-Barrena²⁶, Carlos Montilla-Morales²⁷, Gema Bonilla²⁸, Vicente Torrente-Segarra²⁹, Ana Paula Cacheda³⁰, Maria J. García-Villanueva³¹, Clara Moriano Morales³², Concepción Fito Manteca³³, Nuria Lozano Rivas³⁴, Cristina Bohórquez³⁵ and Jose-Maria Pego-Reigosa³⁶, ¹University Hospital of Vigo, Department of Rheumatology. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute (IISGS), Vigo, Spain, ²Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ³Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ⁴Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁵IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁶Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁷Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁸Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁹Department of Rheumatology, Doctor Negrín University Hospital, Las Palmas de Gran Canaria, Spain, ¹⁰Rheumatology Department Hospital Gregorio Marañón, Madrid, Spain, ¹¹Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹²Rheumatology, Hospital La Princesa, Madrid, Spain, ¹³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁵Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ¹⁶Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹⁷Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁸Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁹Severo Ochoa Hospital, Madrid, Spain, ²⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ²¹Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ²²Department of Rheumatology, Hospital Villajoyosa, Alicante, Spain, ²³Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁴Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, ²⁵Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²⁶Galdakao-Usansolo University Hospital, Bilbao, Spain, ²⁷Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²⁸Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁹Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ³⁰Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ³¹Hospital Ramón y Cajal, Madrid, Spain, ³²Rheumatology, Hospital Universitario de León, León, Spain, ³³Complejo Universitario de Navarra, Pamplona, Spain, ³⁴Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³⁵Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, ³⁶Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: In systemic lupus erythematosus (SLE), there is no definition of states of moderate and severe SLE activity. How these states may influence different disease…
Abstract Number: 0108 • ACR Convergence 2023
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
Emily Balczewski, Wenying Liang, Amala Ambati, Yu Zuo, Karandeep Singh and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…
Abstract Number: 2324 • ACR Convergence 2023
Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA
Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…
Abstract Number: 0140 • ACR Convergence 2023
Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Jessica Ellis¹, Anita McGrogan², Neil McHugh², Ben Mulhearn³, Eleanor Korendowych⁴, John Pauling⁵, Ian Bruce⁶, Jenny Humphreys⁷ and Sarah Skeoch¹, ¹University of Bath; Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Bath, Bath, United Kingdom, ³Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Manchester, Stockport, United Kingdom
Background/Purpose: The 2019 EULAR/ACR Classification Criteria allow classification of patients with systemic lupus erythematosus (SLE) for research. They reflect updates in current understanding of SLE…
Abstract Number: 2412 • ACR Convergence 2023
Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice
María del Carmen San José Méndez¹, Uxía Couto Lareo¹, Vanesa Balboa Barreiro², Francisco J. Blanco¹, Bruno de aspe de la iglesia¹, Antonio Atanes Sandoval³, Diego Dios Santos¹, Jesús Carlos Fernández López¹, Mercedes Freire González¹, Guillermo González Arribas¹, Genaro Graña Gil¹, Natividad Oreiro Villar¹, Jose Antonio Pinto Tasende¹, Francisco Javier De Toro Santos¹, Clara Ventin Rodriguez¹, Maite silva díaz³ and Ana Lois Iglesias¹, ¹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²Clinic epidemiology and biostatistics department. Complejo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain
Background/Purpose: Giant cell arteritis (GCA) affects large and medium size arteries. Biopsy was considered the gold standard in the diagnosis1, but in the last years…
Abstract Number: 0298 • ACR Convergence 2023
Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy
Tatiana Cobo¹, Marta Domínguez², Anna Pros³, Jose Luís Tandaipán⁴, Laura Nuño⁵, JULIA MARTINEZ BARRIO⁶, Vega Jovani⁷, Fredeswinda Romero⁸, Maria Esther Ruiz Lucea⁹, Eva Tomero Muriel¹⁰, Ernesto Trallero Araguás¹¹, Javier Narvaez¹², Jordi Camins Fàbregas¹³, ALBERTO MARIANO RUIZ ROMAN¹⁴, Jesus Loarce-Martos¹⁵, Annika Nack¹⁶, Esmeralda Delgado-Frías¹⁷, Francisca Sivera¹⁸, carolina Merino¹⁹, Antonio Juan Mas²⁰, Alejandro Gómez Gómez¹, Jose-Maria Pego-Reigosa²¹, Maria Martin-Lopez²², Jesús Alejandro Valero²³, Carmen carrasco-Cubero²⁴, Mercedes Freire González²⁵, Iñigo Rúa-Figueroa²⁶, Nuria Lozano Rivas²⁷, Julio David Suarez Cuba²⁸, Ana Isabel Turrión Nieves²⁹, María Ángeles Puche Larrubia³⁰ and Patricia Alcocer Amores³¹, ¹Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Department of Rheumatology, Hospital del Mar, Barcelona, Spain, ⁴Department of Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ⁵Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ⁶Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁷Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ⁸IIS-HU Fundación Jiménez Díaz, Madrid, Spain, ⁹Basurto University Hospital, Bilbao, Spain, ¹⁰Rheumatology, Hospital La Princesa, Madrid, Spain, ¹¹Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ¹²Hospital Universitario de Bellvitge, Barcelona, Spain, ¹³Department of Rheumatology, Hospital General de Granollers, Barcelona, Spain, ¹⁴Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁵Ramón y Cajal University Hospital, Madrid, Spain, ¹⁶Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁷Department of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ¹⁸Department of Rheumatology, Hospital General Universitario de Elda, Alicante, Spain, ¹⁹Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ²⁰Hospital Universitario Son Llàtzer, Mallorca, Spain, ²¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ²²Hospital 12 de Octubre, Madrid, Spain, ²³Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, ²⁴Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²⁵Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁶Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²⁷Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁸Department of Rheumatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain, ²⁹Department of Rheumatology, Hospital Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ³⁰Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ³¹Department of Rheumatology, Hospital Universitario HM Sanchinarro, Madrid, Spain
Background/Purpose: Limitations of the 2017 EULAR/ACR classification criteria have been suggested for classifying patients with idiopathic inflammatory myopathies (IIMs) and myositis-specific antibodies (MSAs). On this…
Abstract Number: 2423 • ACR Convergence 2023
Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis
Julio Sanchez Martin¹, Julia Medina Valle¹, Javier Loricera¹, Maria Fe Garcia Reija¹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Classification criteria for vasculitis, including giant cell arteritis (GCA) are under constant revision. In 2022, the American College of Rheumatology (ACR)/European League Against Rheumatism…
Abstract Number: 0356 • ACR Convergence 2023
PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis
Pamela F. Weiss¹, Timothy G. Brandon², Amita Aggarwal³, RUBEN BURGOS-VARGAS⁴, Robert Colbert⁵, Gerd Horneff⁶, Rik Joos⁷, Ronald Laxer⁸, Kirsten Minden⁹, Angelo Ravelli¹⁰, Nicolino Ruperto¹¹, Judith Smith¹², Matthew Stoll¹³, Shirley Tse⁸, Filip Van den Bosch¹⁴, Walter P. Maksymowych¹⁵, Robert Lambert¹⁶, David Biko², Nancy A. Chauvin¹⁷, Michael L. Francavilla¹⁸, Jacob Jaremko¹⁵, Nele Herregods¹⁹, Ozgur Kasapcopur²⁰, Mehmet YILDIZ²¹, Hemalatha Srinivasalu²², Ray Naden²³ and Alison Hendry²⁴, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁴Hospital General de Mexico, Ciudad de México, Mexico, ⁵NIH/NIAMS, Bethesda, MD, ⁶Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ⁷Ghent University, Basel, Switzerland, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, ¹⁰Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹¹IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ¹²University of Wisconsin, Madison, WI, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ¹⁵University of Alberta, Edmonton, AB, Canada, ¹⁶Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ¹⁷The Cleveland Clinic, Hummelstown, PA, ¹⁸University of South Alabama College of Medicine, Mobile, AL, ¹⁹Ghent University Hospital, Ghent, Belgium, ²⁰Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²¹Istanbul University-Cerrahpasa Department of Pediatric Rheumatology, Istanbul, Turkey, ²²Children's National Hospital, Washington, DC, ²³Auckland City Hospital, Auckland, New Zealand, ²⁴Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand
Background/Purpose: The Paediatric Rheumatology International Trials Organisation (PRINTO) recently undertook an effort to better harmonize the pediatric and adult arthritis criteria. These provisional criteria are…
Abstract Number: 2480 • ACR Convergence 2023
Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI
Victoria Konzett¹, Andreas Kerschbaumer², Josef S Smolen³, Eirik Kristianslund⁴, Sella Provan⁴, Tore Kvien⁵ and Daniel Aletaha⁶, ¹Medical University of Vienna, Wien, Austria, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria
Background/Purpose: Measures of improvement and state of disease activity are well-established in rheumatoid arthritis (RA), whereas distinct classifiers for worsening (“flare”) are lacking to date.…
Abstract Number: 0378 • ACR Convergence 2023
Characteristics of Macrophage Activation Syndrome in Systemic JIA Patients Receiving Anakinra as First-line Treatment
Remco Erkens¹, Laura Huber¹, Anouk Verwoerd¹, Greta Rogani¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Wineke Armbrust³, Elizabeth Legger⁴, Sylvia Kamphuis⁵, Ellen Schatorjé⁶, Esther Hoppenreijs⁷, Joost Swart⁸, Marc Jansen¹, Jorg van Loosdregt¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University Medical Hospital Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁶University Medical Center Radboud, Nijmegen, Netherlands, ⁷Radboud University Medical Center, Nijmegen, Netherlands, ⁸Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe inflammatory disease with auto-inflammatory characteristics. The introduction of targeted biologic therapies has revolutionized the treatment and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].